Status:
UNKNOWN
Study of Microwave Spherical Ablation and Traditional Microwave Ablation in Single Hepatocellular Carcinoma ≤5cm
Lead Sponsor:
Tianjin Third Central Hospital
Conditions:
Hepatocellular Cancer
Microwave Ablation
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
Comparison of the progression-free survival, overall survival, local progression rates, complete ablation rates and the complications rate of MSA and traditional MWA in the treatment of single hepatoc...
Detailed Description
HCC is a serious threat to the health of people，Early treatment of HCC results in a good prognosis for patients. Microwave ablation (MWA) is an important method for the treatment of early HCC. The tra...
Eligibility Criteria
Inclusion
- Patient has high risk factors for HCC and was first diagnosed of HCC by by contrast-enhanced imaging (CECT/CEMRI/CEUS) and/or pathology ;
- Age range 18 to 75 years old;
- Single lesion with tumor diameter ≤5cm;
- Patient refuses surgery and determines to undergo microwave ablation
- Liver function Child Pugh A or B;
- No extrahepatic metastasis or portal invasion;
- Patient signs the informed consent.
Exclusion
- The lesion has received treatment, including local ablation therapy and TACE therapy, etc;
- With portal vein invasion or extrahepatic metastases;
- Patient is with severe cardiopulmonary insufficiency.
- Patient is a pregnant or breastfeeding women.
- Patient is considered to be unsuitable to participate in the study
Key Trial Info
Start Date :
June 22 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2025
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT05361538
Start Date
June 22 2022
End Date
June 1 2025
Last Update
December 14 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tianjin Third Central Hospital
Tianjin, Tianjin Municipality, China, 300170